Summarized by Masters of Longevity from Longevity Technology.
A biotech–big pharma licensing story that previews a deal-focused article about an investigational RNAi fat-loss program and its commercial terms.
Key Takeaways
- Rona granted Roche an exclusive worldwide license for an RNAi candidate targeting ALK7 in adipose tissue.
- Rona will receive up to $100 million in upfront and near-term milestone payments.
- Rona is eligible for up to $1.06 billion in development, regulatory, and commercial milestones plus tiered royalties.
